Weight Changes From Glucagon‐Like Peptide‐1 Receptor Agonist Use and Discontinuation: A Retrospective Cohort Study
Among this real-world sample, GLP-1 use was associated with more modest weight loss than has been demonstrated in randomized controlled trials.
Authors
- Scott L. Zeger (ORCID: https://orcid.org/0000-0001-8907-1603)
- Hemalkumar B. Mehta (ORCID: https://orcid.org/0000-0001-9134-6370)
- G. Caleb Alexander (ORCID: https://orcid.org/0000-0002-5622-2986)
- Sydney V. Lewis (ORCID: https://orcid.org/0000-0003-4489-3982)
- Xuya Xiao (ORCID: https://orcid.org/0000-0003-4198-7502)
- Yizhen Xu (ORCID: https://orcid.org/0000-0002-4650-5851)
Institutions
- Johns Hopkins University (US)
- University of Utah (US)
- Johns Hopkins Medicine (US)
Publication Details
- Journal
- Obesity
- Published
- 2025-11-21
- DOI
- https://doi.org/10.1002/oby.70076
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00